Last reviewed · How we verify
detrusor infection of Botulinum toxin
detrusor infection of Botulinum toxin is a Small molecule drug developed by Centre d'Investigation Clinique et Technologique 805. It is currently in Phase 2 development.
At a glance
| Generic name | detrusor infection of Botulinum toxin |
|---|---|
| Sponsor | Centre d'Investigation Clinique et Technologique 805 |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin (PHASE3)
- Toxin Retrospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- detrusor infection of Botulinum toxin CI brief — competitive landscape report
- detrusor infection of Botulinum toxin updates RSS · CI watch RSS
- Centre d'Investigation Clinique et Technologique 805 portfolio CI
Frequently asked questions about detrusor infection of Botulinum toxin
What is detrusor infection of Botulinum toxin?
detrusor infection of Botulinum toxin is a Small molecule drug developed by Centre d'Investigation Clinique et Technologique 805.
Who makes detrusor infection of Botulinum toxin?
detrusor infection of Botulinum toxin is developed by Centre d'Investigation Clinique et Technologique 805 (see full Centre d'Investigation Clinique et Technologique 805 pipeline at /company/centre-d-investigation-clinique-et-technologique-805).
What development phase is detrusor infection of Botulinum toxin in?
detrusor infection of Botulinum toxin is in Phase 2.